STRAIN OF BACTERIUM BRUCELLA ABORTUS USED FOR ASSAY OF IMMUNOGENIC ACTIVITY OF VACCINES AGAINST BRUCELLOSIS IN AGRICULTURE ANIMALS Russian patent published in 2000 - IPC

FIELD: veterinary science, microbiology. SUBSTANCE: new strain of Brucella abortus is able to reproduce stably in nutrient media containing growth inhibitor of brucella of vaccine strains and foreign microflora. Bis-triphenylanhydrocarbinol oxalate at concentration 0.001% is used as growth inhibitor. Strain does not show pathogenicity for animals and humans. Strain Brucella abortus is deposited in microorganism collection of VGNKI at N KB 13/100 DEP. Immunogenic activity of antibrucellosis vaccine is determined by the rate of elimination of brucella of control strain B. abortus VGNKI N KB 13/100 DEP from immunized animals body. Laboratory animals (mice, guinea pigs) are immunized with antibrucellosis vaccine followed by administration of culture of control strain B. abortus VGNKI N KB 13/100 and animals are killed. Then bacteriological studies of lymph nodes and viscera are carried out. For this purpose pathologic material is sown in nutrient media containing bis-triphenylanhydrocarbinol oxalate at concentration 0.01%. Animals are considered to be immune if brucella of control strain are eliminated from their body completely for definite period. Use of control vaccine strain Brucella abortus N KB 13/100 ensures to safe the control of biopreparations efficiency, increase numbers of series to be tested, enhance vaccine quality significantly and enhance effectiveness of specific prophylaxis of brucellosis significantly. Invention is designated for control of biopreparations used against brucellosis in agriculture animals. EFFECT: new strain indicated above, effective control of biopreparations. 4 tbl, 5 ex